Abstracts Archive - Page 1166 of 2425 - ACR Meeting Abstracts

Abstract Number: 2423 • 2018 ACR/ARHP Annual Meeting
Births to Women with Systemic Lupus Erythematosus Can be Identified Accurately in the Electronic Health Record
Ashley Blaske¹, Amanda M. Eudy², Jim C. Oates³, Megan E. B. Clowse² and April Barnado⁴, ¹Medicine and Pediatrics, Vanderbilt University Medical Center, Nashville, TN, ²Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, ³Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Studying births in women with systemic lupus erythematosus (SLE) is difficult given its rarity and the challenges of randomized trials. While the electronic health…
Abstract Number: 2424 • 2018 ACR/ARHP Annual Meeting
Bisphosphonates during Pregnancy: A Systematic Review Sayanika Kaur MD Fellow Drexel Rheumatology, Mojdeh Khaamesi MD Resident Internal Medicine Arundathi Jayatilleke MD Program Director Drexel Rheumatology
Sayanika Kaur¹, Mojdeh Khaamesi² and Arundathi ‎ Jayatilleke ‎¹, ¹Rheumatology, Drexel University COM, Philadelphia, PA, ²Internal Medicine, Drexel University COM, Philadelphia, PA
Background/Purpose: Recent ACR guidelines on prevention and treatment of CS-induced osteoporosis state that women of childbearing potential who are at moderate-to-high risk of fracture should…
Abstract Number: 2425 • 2018 ACR/ARHP Annual Meeting
The Impact of Biologic Treatment for Rheumatoid Arthritis Patients Who Hope to Conceive
Hiromi Shimada, Taichi Miyagi, Mikiya Kato, Risa Wakiya, Shusaku Nakashima, Tomohiro Kameda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Previous reports revealed that it was difficult for rheumatoid arthritis (RA) patients to conceive1). Age, nulliparity, disease activity, NSAIDs, corticosteroid was known as the…
Abstract Number: 2426 • 2018 ACR/ARHP Annual Meeting
Defining a Standardized Core Data Set for Pregnancy Registers in Rheumatic Diseases – an European Approach
Yvette Meißner¹, Anja Strangfeld¹, Nathalie Costedoat-Chalumeau^2,3, Frauke Förger^4,5, Anna Moltó⁶, Marianne Wallenius^7,8 and Rebecca Fischer-Betz⁹, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Université Paris-Descartes, Paris, France, ³Internal Medicine, Hopital Cochin, Paris, France, ⁴University of Bern, Bern, Switzerland, ⁵Rheumatology, Clinical Immunology and Allergology, Inselspital-University Hospital, Bern, Switzerland, ⁶Rheumatology B Department, Paris Descartes University, Cochin Hospital, AP-HP,Paris, Paris, France, ⁷Norwegian University of Science and Technology, Trondheim, Norway, ⁸St. Olav's University Hospital, Trondheim, Norway, ⁹Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: Robust data on the outcomes of pregnancy and influence of drug exposure in various inflammatory rheumatic diseases (IRD) are needed. Joint analyses of data…
Abstract Number: 2427 • 2018 ACR/ARHP Annual Meeting
Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Marianna Meroni¹, Maria De Santis², Elena Generali², Angela Ceribelli³, Marta Caprioli³, Giacomo Maria Guidelli², Natasa Isailovic², Gaetano Maria Fara⁴, Carlo Selmi² and Maurizio Cutolo⁵, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁴Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy
Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern,…
Abstract Number: 2428 • 2018 ACR/ARHP Annual Meeting
Correlation between Antibodies to the Phosphotidylserine/Prothrombin Complex (aPS/PT) and Anti-β2glycoprotein-1-Domain 1 (anti-β2GP1-D1) and Vascular Thrombosis (VT) and/or Pregnancy Morbidity (PM)
Eric Campbell¹, Tania Pannu¹, Marvin J. Fritzler², Michelle Jung³, Claire Barber⁴, Yvan St. Pierre⁵ and Ann E. Clarke², ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: aPS/PT is considered to be a risk factor for vascular thrombosis (VT) and/or pregnancy morbidity (PM). Anti-β2GP1-D1 is potentially superior to anti-β2GP1 in predicting…
Abstract Number: 2429 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study
Laura Andreoli¹, Maria Chiara Gerardi², Chiara Bazzani³, Matteo Filippini³, Micaela Fredi², Roberto Gorla³, Maria Grazia Lazzaroni², Cecilia Nalli², Marco Taglietti³, Andrea Lojacono⁴, Sonia Zatti⁴, Mario Motta⁵ and Angela Tincani², ¹Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁴Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁵Neonatology and NICU, Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Treatment with tumor necrosis factors inhibitors (TNFi) during pregnancy may be required to control maternal disease which can be a threat for maternal-fetal well-being.…
Abstract Number: 2430 • 2018 ACR/ARHP Annual Meeting
Pregnancy in Women with Ankylosing Spondylitis Is Not Associated with Poor Obstetric Outcomes: Analysis of Nationwide Inpatient Sample Database 2003-2011
Vikas Majithia and Shweta Kishore, Division of Rheumatology, University of Mississippi Medical Center, Jackson, MS
Background/Purpose: Outcomes of pregnancy are well studied in a number of rheumatic diseases such as Rheumatoid Arthritis (RA) and systemic lupus erythematosus. When compared, there…
Abstract Number: 2431 • 2018 ACR/ARHP Annual Meeting
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Chelsey J F Smith¹, Arthur Kavanaugh² and Christina D Chambers³, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: The goal of this prospective cohort study is to add to the limited data on birth outcomes in psoriatic arthritis (PsA) and ankylosing spondylitis…
Abstract Number: 2432 • 2018 ACR/ARHP Annual Meeting
Peripartum Issues in the Inflammatory Arthritis (IA) Patient: A Survey of the Rapport (Rheumatoid Arthritis Pharmacovigilence Program and Outcomes Research in New Therapies) Registry
Tharindri Dissanayake¹, Stephanie Keeling² and Walter P. Maksymowych³, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, University of Alberta, Edmonton, AB, Canada, ³CaRE Arthritis, Edmonton, AB, Canada
Background/Purpose: Multiple issues surround the peripartum period for IA patients including medication use, risk of disease flare and potential impact on neonatal outcomes. We aimed…
Abstract Number: 2433 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Undifferentiated Connective Tissue Disease- a Single Academic Center’s Experience
Katherine Kaufman¹, Amanda M. Eudy¹, Nathaniel J. Harris², Laura Neil³ and Megan E. B. Clowse¹, ¹Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Medicine, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC
Background/Purpose: SLE patients have poorer pregnancy outcomes than healthy patients, including a lower rate of live birth and higher rates of small for gestational age…
Abstract Number: 2434 • 2018 ACR/ARHP Annual Meeting
Obstetric Outcomes in Women with Takayasu Arteritis: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal² and Vikas Majithia¹, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²University of Mississippi, Jackson, MS
Background/Purpose: Few case reports and series suggest adverse pregnancy outcomes in patients with Takayasu Arteritis (TA). This study was undertaken to determine the frequency of…
Abstract Number: 2435 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes Among Women with Rare Autoimmune Diseases
Jon Golenbiewski, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: Autoimmune disease in pregnancy creates the potential for increased complications and poor pregnancy outcomes. There is a paucity of outcomes data in less-common autoimmune…
Abstract Number: 2436 • 2018 ACR/ARHP Annual Meeting
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more…
Abstract Number: 2437 • 2018 ACR/ARHP Annual Meeting
Analysis of Occurrence of Small for Gestational Age Infants in Women with Systemic Lupus Erythematosus
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a higher risk of fetal growth restriction and birth of small for gestational age (SGA) concepts. Fetuses…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].